Richland, WA, March 20, 2018 — Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board. Tariq Shah BSc. DipMS is the founder and director of Oncologize, a consulting company that provides a direct link between the biotech companies and veterinary oncologists within the United StatesTariq Shah has been working within Animal Health for 25 years. A graduate in Marine Biology from the University of Liverpool, United Kingdom, he has held managerial positions for both veterinary pharmaceutical companies and veterinary diagnostic laboratories. Since he came to the US in 2008, he has worked with veterinary oncologists across America, conducting research and commercializing diagnostic technology.He holds an adjunct faculty position at the University of Missouri College of Veterinary Medicine, which is our key canine testing center. In 2017 he established Oncologize, a pioneering company designed to support and assist organizations in their development and commercialization of oncology products.Tariq Shan said he is extremely happy to be supporting IsoPetTM in this exciting venture and to work with Dr. Alice Villalobus, the Chair of the Board. Dr. Mike Korenko stated â€œTariqâ€™s experience is very relevant to our thrust to commercialize IsoPetTM by partnering with the private clinics consortiums.â€�About Vivos Inc. (OTC: RDGL)Currently, the Company is engaged in the development of a Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and people. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.IsoPetTM for treating animals is the same product as RadioGelTM for treating humans. The Food and Drug Administration advised using different names in order to avoid confusion and cross-use.IsoPetTM is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor.
This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.IsoPetTM also has a short half-life â€“ delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.The IsoPetTM Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.The Company recently obtained classification clarification from the FDA that they are a device for therapy on skin cancer in animals and they approved our label. No other regulatory approval is required for skin cancer, which is the largest market sector. RDGL is positioning itself so that after this demonstration phase, the Company can begin to generate revenues through the sale of IsoPetTM to private animal clinic consortiums.The Company is also engaging the FDA for permission to use RadioGelTM for the treatment of advanced basal and squamous cell skin cancers in humans.Safe Harbor StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.CONTACT:
Michael K. Korenko, President & CEO